Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia

2005912 citationsJournal Articlebronze Open Access

Authors

Claire Harrison · St. Thomas Hospital

Peter J. Campbell · University of Cambridge

Georgina Buck · Oxford Centre for Diabetes, Endocrinology and Metabolism

Keith Wheatley · University of Birmingham

Clare East · University of Cambridge

D. Bareford · National Health Service

Bridget S. Wilkins

Abstract

Hydroxyurea plus low-dose aspirin is superior to anagrelide plus low-dose aspirin for patients with essential thrombocythemia at high risk for vascular events.

Topics & Keywords

Myeloproliferative Neoplasms: Diagnosis and Treatment Kruppel-like factors research Chronic Myeloid Leukemia Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 353, Issue 1, pp. 33-45

DOI: 10.1056/nejmoa043800

Field-Weighted Citation Impact: 23.66